`____________
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`
`
`
`APPLE INC.,
`
`Petitioner
`
`v.
`PARUS HOLDINGS, INC.,
`
`Patent Owner
`___________
`
`
`
`Case No. IPR2020-00686
`U.S. Patent No. 7,076,431
`____________
`
`
`PETITIONER APPLE INC.’S OBJECTIONS TO EVIDENCE PURSUANT
`TO 37 C.F.R. § 42.64(b)(1)
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.64(b)(1), Petitioner Apple Inc. (“Petitioner”)
`
`submits the following objections to evidence that Parus Holdings, Inc. (“Patent
`
`Owner”) served in its Patent Owner Sur-Reply (Paper 21). These objections are
`
`timely filed and served within five business days of Patent Owner’s May 5, 2021,
`
`Patent Owner Sur-Reply.
`
`Evidence
`
`Objections
`
`Exhibit 2026
`(Dragon Naturally
`Speaking v.12 User Guide)
`
`
`FRE 401, 402, and 403: Petitioner
`objects to this evidence on the grounds
`that it is irrelevant and its probative
`value is substantially outweighed by a
`danger of unfair prejudice, confusing
`the issues, and wasting time.
`
`FRE 901 and 902: Petitioner objects to
`this evidence on the grounds that it is
`lacking authentication under Federal
`Rules of Evidence (“FRE”) 901 because
`sufficient evidence has not been
`provided to establish their authenticity
`or dates prior to the critical date of the
`’431 Patent. Patent Owner has not
`submitted evidence to authenticate these
`exhibits or to otherwise establish that
`they are what Patent Owner claims them
`to be.
`
`37 C.F.R. § 42.123(b): Petitioner
`objects to this evidence on the grounds
`that the evidence is a late submission of
`supplemental information filed without
`authorization.
`See Mallinckrodt
`Pharmaceuticals Ireland Limited v.
`Biovie, Inc., IPR2018-00974, Paper 34
`at 7–10.
`
`
`
`1
`
`
`
`Exhibit 2027 (Declaration of Benedict
`Occhiogrosso in Support of Patent
`Owner’s Sur-Reply
`to Petitioner's
`Reply to Patent Owner’s Response)
`
`Paper 21, specifically portions of Paper
`21 that rely on Exs. 2026 and 2027 (e.g.,
`Section II.C.1)
`
`FRE 401, 402, and 403: Petitioner
`objects to this evidence on the grounds
`that it is irrelevant and its probative
`value is substantially outweighed by a
`danger of unfair prejudice, confusing
`the issues, and wasting time.
`
`37 C.F.R. § 42.123(b): Petitioner
`objects to this evidence on the grounds
`that the evidence is a late submission of
`supplemental information filed without
`authorization.
`See Mallinckrodt
`Pharmaceuticals Ireland Limited v.
`Biovie, Inc., IPR2018-00974, Paper 34
`at 7–10.
`37 C.F.R. § 42.123(b): Petitioner
`objects to this evidence on the grounds
`that the evidence is a late submission of
`supplemental information filed without
`authorization.
`See Mallinckrodt
`Pharmaceuticals Ireland Limited v.
`Biovie, Inc., IPR2018-00974, Paper 34
`at 7–10.
`
`Petitioner objects to Exhibits 2026 and 2027 and the related portions of Patent
`
`
`
`
`
`Owner’s Sur-Reply. These exhibits constitute late submissions of supplemental
`
`information under 37 C.F.R. § 42.123(b). Per the November 2019 Trial Practice
`
`Guide, “The sur-reply may not be accompanied by new evidence other than
`
`deposition transcripts of the cross-examination of any reply witness.” This Board
`
`has previously expunged late-filed exhibits and stricken the related portions of the
`
`Patent Owner’s Sur-Reply in this same scenario. See Mallinckrodt Pharmaceuticals
`
`Ireland Limited v. Biovie, Inc., IPR2018-00974, Paper 34 at 7–10 (striking portions
`2
`
`
`
`
`
`of the Sur-Reply related to a late-filed exhibit); Lenovo Holding Company, Inc. v.
`
`Dodots Licensing Solutions LLC, IPR2019-01279, Paper 37 at 34–34 (striking a
`
`Supplemental Declaration filed with a Sur-Reply). This is consistent with the
`
`Board’s obligation to “secure the just, speedy, and inexpensive resolution of every
`
`proceeding,” as allowing a declaration in a sur-reply “would require the opportunity
`
`for cross-examination and potentially
`
`further substantive briefing
`
`from
`
`Petitioner….” Taiwan Semiconductor Manufacturing Company, LTD. v. Godo
`
`Kaisha IP Bridge 1, IPR2016-01246, Paper 28 at 3.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`ERISE IP, P.A.
`
`
`
`
`BY: /s/ Jennifer C. Bailey
`Jennifer C. Bailey Reg. No. 52,583
`Adam P. Seitz, Reg. No. 52,206
`7015 College Blvd., Suite 700
`Overland Park, KS 66211
`P: (913) 777-5600
`F: (913) 777-5601
`jennifer.bailey@eriseip.com
`adam.seitz@eriseip.com
`
`ATTORNEYS FOR PETITIONER
`APPLE INC.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE ON PATENT OWNER
`UNDER 37 C.F.R. § 42.6
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on May 7, 2021
`the foregoing Petitioner Apple Inc.’s Objections to Evidence Pursuant to 37 C.F.R.
`§ 42.64(b)(1) was served via electronic filing with the Board and via Electronic Mail
`on the following practitioners of record for Patent Owner:
`
`
`
`
`
`
`
`
`
`
`
`
`
`Michael J. McNamara (mmcnamara@mintz.com)
`Michael T. Renaud (mtrenaud@mintz.com)
`William A. Meunier (wameunier@mintz.com)
`Andrew H. DeVoogd (ahdevoogd@mintz.com)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Jennifer C. Bailey
`Jennifer C. Bailey Reg. No. 52,583
`
`ATTORNEY FOR PETITIONER
`
`
`
`
`
`
`4
`
`